MCID: EXT010
MIFTS: 49

Extramedullary Plasmacytoma

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Extramedullary Plasmacytoma

MalaCards integrated aliases for Extramedullary Plasmacytoma:

Name: Extramedullary Plasmacytoma 12 15 73
Plasmacytoma, Extramedullary 12
Extraosseous Plasmacytoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3720
ICD10 33 C90.2 C90.20
NCIt 50 C4002
SNOMED-CT 68 10639003
UMLS 73 C0278619

Summaries for Extramedullary Plasmacytoma

MalaCards based summary : Extramedullary Plasmacytoma, also known as plasmacytoma, extramedullary, is related to plasmacytoma and myeloma, multiple. An important gene associated with Extramedullary Plasmacytoma is B2M (Beta-2-Microglobulin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Bortezomib and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and breast, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Related Diseases for Extramedullary Plasmacytoma

Diseases related to Extramedullary Plasmacytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
# Related Disease Score Top Affiliating Genes
1 plasmacytoma 33.1 B2M IGKC IL6
2 myeloma, multiple 30.7 B2M CCND1 IL6 MYOM2
3 solitary osseous plasmacytoma 30.0 B2M MYOM2
4 marginal zone b-cell lymphoma 30.0 BCL2 CCND1
5 lymphoma, mucosa-associated lymphoid type 29.8 BCL2 CCND1 IGKC
6 leukemia, chronic lymphocytic 29.7 B2M BCL2 CCND1
7 extramedullary soft tissue plasmacytoma 10.4
8 lymphoma 10.3
9 amyloidosis 10.2
10 squamous cell carcinoma 10.1
11 adenocarcinoma 10.1
12 lymphoma, small cleaved-cell, diffuse 10.1 BCL2 CCND1
13 pyelitis 10.1 B2M IL6
14 post-transplant lymphoproliferative disease 10.1 B2M IL6
15 hemorrhagic fever 10.1 B2M IL6
16 indolent myeloma 10.1 B2M MYOM2
17 intravascular large b-cell lymphoma 10.1 B2M BCL2
18 waldenstroem's macroglobulinemia 10.1 B2M MYOM2
19 amyloid tumor 10.1 B2M MYOM2
20 hidradenocarcinoma 10.1 BCL2 CCND1
21 non-secretory myeloma 10.1 B2M MYOM2
22 keratocystic odontogenic tumor 10.1 BCL2 CCND1
23 meningoencephalitis 10.1 B2M IL6
24 streptococcal toxic-shock syndrome 10.1 IL6 MYOM2
25 polyclonal hypergammaglobulinemia 10.1 IL6 MYOM2
26 hemorrhagic fever with renal syndrome 10.1 B2M IL6
27 impetigo 10.1 IL6 MYOM2
28 osteosclerotic myeloma 10.1 IL6 MYOM2
29 human herpesvirus 8 10.1 BCL2 IL6
30 syphilis 10.1 B2M BCL2
31 poems syndrome 10.1 IL6 MYOM2
32 necrotizing fasciitis 10.1 IL6 MYOM2
33 human immunodeficiency virus infectious disease 10.1 B2M IL6
34 carpal tunnel syndrome 10.1 B2M IL6
35 nodular goiter 10.1 BCL2 IL6
36 uterine anomalies 10.1 CCND1 IL6
37 commensal bacterial infectious disease 10.1 IL6 MYOM2
38 intussusception 10.1
39 pancreatic cancer 10.1
40 b-cell lymphomas 10.1
41 leukemia 10.1
42 ulcerative colitis 10.1
43 colitis 10.1
44 sarcoma 10.1
45 obstructive jaundice 10.1
46 thyroiditis 10.1
47 rheumatic fever 10.1 IL6 MYOM2
48 rheumatic heart disease 10.0 IL6 MYOM2
49 retinal cancer 10.0 CCND1 CDKN1A
50 cardiac tamponade 10.0

Graphical network of the top 20 diseases related to Extramedullary Plasmacytoma:



Diseases related to Extramedullary Plasmacytoma

Symptoms & Phenotypes for Extramedullary Plasmacytoma

MGI Mouse Phenotypes related to Extramedullary Plasmacytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.72 B2M BCL2 CCND1 CDKN1A IL6
2 endocrine/exocrine gland MP:0005379 9.65 B2M BCL2 CCND1 CDKN1A IL6
3 integument MP:0010771 9.55 B2M BCL2 CCND1 CDKN1A IL6
4 neoplasm MP:0002006 9.35 B2M BCL2 CCND1 CDKN1A IL6
5 reproductive system MP:0005389 9.02 B2M BCL2 CCND1 CDKN1A IL6

Drugs & Therapeutics for Extramedullary Plasmacytoma

Drugs for Extramedullary Plasmacytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 228)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
5
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
7
Melphalan Approved Phase 3,Phase 2 148-82-3 4053 460612
8
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
9
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
10
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
11
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
12
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
15
Dalteparin Approved Phase 3 9005-49-6
16
Ondansetron Approved Phase 3 99614-02-5 4595
17
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
18
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
19
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
20
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
21
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
22
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
23
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
24
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
25
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
26 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
27
protease inhibitors Phase 3,Phase 2,Phase 1
28 Proteasome Inhibitors Phase 3,Phase 1
29 Hormone Antagonists Phase 3,Phase 2,Phase 1
30 Hormones Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
32 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
33 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
34 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
35 Autonomic Agents Phase 3,Phase 2,Phase 1
36 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
38 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
39 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
40 Alkylating Agents Phase 3,Phase 2,Phase 1
41 Antiemetics Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
44 BB 1101 Phase 3,Phase 2,Phase 1
45 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
46 glucocorticoids Phase 3,Phase 2,Phase 1
47 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
49 Anesthetics, Dissociative Phase 3
50 Anesthetics, General Phase 3

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. Completed NCT00405756 Phase 3 Lenalidomide: Double-blind Induction;Melphalan;Prednisone;Aspirin;Placebo;Lenalidomide: Double-blind Maintenance;Lenalidomide: Open-label
4 A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Completed NCT00424047 Phase 3 CC-5013 plus dexamethasone;Dexamethasone plus Placebo
5 A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma Completed NCT00478777 Phase 3 Lenalidomide;dexamethasone
6 A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma Completed NCT00622336 Phase 3 Lenalidomide
7 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
8 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
9 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
12 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
13 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
14 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
15 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
16 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
17 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
18 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
19 Beta Alethine in Treating Patients With Myeloma Unknown status NCT00006466 Phase 1, Phase 2 beta alethine
20 Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma Completed NCT01478048 Phase 2 Bortezomib;Dexamethasone;Dexamethasone;Dexamethasone;Dexamethasone
21 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
22 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
23 SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant Completed NCT00002657 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;methotrexate;prednisone;vincristine sulfate
24 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
25 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
26 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
27 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
28 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
29 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
30 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
31 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
32 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
33 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2
34 Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation Completed NCT00005606 Phase 2
35 Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Recruiting NCT02547662 Phase 2 Dexamethasone;Ixazomib Citrate;Pomalidomide
36 Short Course Daratumumab in Patients With Multiple Myeloma Recruiting NCT03490344 Phase 2 Daratumumab;Lenalidomide
37 Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma Active, not recruiting NCT01849783 Phase 2 dexamethasone;cisplatin;doxorubicin;cyclophosphamide;etoposide;bortezomib;thalidomide;melphalan
38 S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma Terminated NCT00109889 Phase 2
39 Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Terminated NCT00337506 Phase 2 Dexamethasone;velcade
40 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
41 Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer Unknown status NCT00004036 Phase 1 amifostine trihydrate;carboplatin;cyclophosphamide
42 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
43 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction Completed NCT00025415 Phase 1 imatinib mesylate
44 Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone Completed NCT01241292 Phase 1
45 PS-341 in Treating Patients With Advanced Cancer Completed NCT00006362 Phase 1 bortezomib
46 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy Completed NCT00005634 Phase 1 vorinostat
47 Decitabine in Treating Patients With Melanoma or Other Advanced Cancer Completed NCT00002980 Phase 1 decitabine
48 Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer Completed NCT00003451 Phase 1
49 Combination Chemotherapy in Treating Patients With Advanced Cancer Completed NCT00003331 Phase 1 fluorouracil;leucovorin calcium;topotecan hydrochloride
50 Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer Completed NCT00003082 Phase 1

Search NIH Clinical Center for Extramedullary Plasmacytoma

Genetic Tests for Extramedullary Plasmacytoma

Anatomical Context for Extramedullary Plasmacytoma

MalaCards organs/tissues related to Extramedullary Plasmacytoma:

41
Bone, Bone Marrow, Breast, Colon, Thyroid, Pancreas, B Cells

Publications for Extramedullary Plasmacytoma

Articles related to Extramedullary Plasmacytoma:

(show top 50) (show all 562)
# Title Authors Year
1
Extramedullary plasmacytoma. ( 29496243 )
2018
2
Treatment of relapsed multiple myeloma complicated by cardiac extramedullary plasmacytoma with D-PACE chemotherapy. ( 29523615 )
2018
3
Atypical Presentation of Extramedullary Plasmacytoma. ( 29559881 )
2018
4
Extramedullary plasmacytoma of the trachea: A case report and review of the literature. ( 29504982 )
2018
5
Gastrointestinal manifestations of extramedullary plasmacytoma: a narrative review and illustrative case reports. ( 29692194 )
2018
6
Extramedullary plasmacytoma of the testis: A case report. ( 29204364 )
2018
7
Collet-Sicard Syndrome Attributable to Extramedullary Plasmacytoma of the Jugular Foramen. ( 29191538 )
2018
8
Pattern of care and impact of prognostic factors on the outcome of head and neck extramedullary plasmacytoma: a systematic review and individual patient data analysis of 315 cases. ( 29224044 )
2018
9
Primary extramedullary plasmacytoma of the sigmoid colon with perforation: a case report. ( 29619633 )
2018
10
Extramedullary plasmacytoma: rare neoplasm of parotid gland. ( 29301803 )
2018
11
A Case of Multiple Myeloma Associated with Extramedullary Plasmacytoma of the Gallbladder Manifesting as Acute Cholecystitis. ( 30050743 )
2018
12
Solitary extramedullary plasmacytoma of the rectum complicating ulcerative colitis. ( 30238285 )
2018
13
Five cases of orbital extramedullary plasmacytoma: diagnosis and management of an aggressive malignancy. ( 29985709 )
2018
14
Extramedullary Plasmacytoma of the Pancreas Complicated with Left-Sided Portal Hypertension-a Case Report and Literature Review. ( 30033507 )
2018
15
Extramedullary plasmacytoma of the larynx: Literature review and report of a case who subsequently developed acute myeloid leukemia. ( 30127889 )
2018
16
Concomitant Extramedullary Plasmacytoma in the Oropharynx and Hypopharyngeal Squamous Cell Carcinoma. ( 30155331 )
2018
17
Pancreatic Extramedullary Plasmacytoma Presenting as a Pancreatic Mass. ( 30262989 )
2018
18
Solitary Extramedullary Plasmacytoma Mimicking Acute Subdural Hematoma. ( 30268553 )
2018
19
Primary solitary extramedullary plasmacytoma progressing to multiple bone plasmacytomas: a rare condition with therapeutic dilemmas. ( 30335051 )
2018
20
Retroperitoneal extramedullary plasmacytoma: A case report and review of the literature. ( 30431616 )
2018
21
Sudden and unexpected death due to intracranial sellar extramedullary plasmacytoma. ( 30503990 )
2018
22
Uterine Extramedullary Plasmacytoma as a Primary Manifestation of Multiple Myeloma. ( 28834996 )
2017
23
Extramedullary Plasmacytoma Arising From the Anterior Mediastinum. ( 28431708 )
2017
24
Clinical findings in 25 patients with sinonasal or nasopharyngeal extramedullary plasmacytoma in a four-decade single-centre series. ( 28537101 )
2017
25
Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients. ( 29142463 )
2017
26
Extramedullary plasmacytoma occuring in ileocecum: A case report and literature review. ( 29390503 )
2017
27
Extramedullary plasmacytoma of the testicle. ( 29205163 )
2017
28
Rare Presentation of Primary Extramedullary Plasmacytoma as Lip Lesion. ( 28409043 )
2017
29
Strategy for the treatment and follow-up of sinonasal solitary extramedullary plasmacytoma: a case series. ( 28793931 )
2017
30
Extramedullary plasmacytoma of the lateral rectus muscle. ( 28267386 )
2017
31
Primary extramedullary plasmacytoma mimicking oral lichen planus. ( 28944756 )
2017
32
An extramedullary plasmacytoma in the kidney of a 14-year-old girl: Case report and review of the literature. ( 28178171 )
2017
33
Extramedullary plasmacytoma mimicking pancreatic cancer: A case report and literature review. ( 28663530 )
2017
34
Marginal zone B-cell lymphoma mimicking extramedullary plasmacytoma and the clinical outcome after treatment. ( 28507591 )
2017
35
Oral extramedullary plasmacytoma in a HIV positive patient. ( 27894848 )
2017
36
Multiple Extramedullary Plasmacytoma in a Setting of Complete Bone Marrow Remission: Food for Thought. ( 29340123 )
2017
37
Solitary Extramedullary Plasmacytoma of the Cricoid Cartilage-Case Report. ( 29230383 )
2017
38
Unusual Cause of Sphenoidal Sinus Mass: Extramedullary Plasmacytoma. ( 27779089 )
2017
39
Extramedullary plasmacytoma in the airway of an HIV-positive child. ( 28834349 )
2017
40
Extramedullary Plasmacytoma of the Oral Cavity in a Young Man: a Case Report. ( 27284562 )
2016
41
Atrophoderma of Pasini and Pierini associated with extramedullary plasmacytoma. ( 27443586 )
2016
42
Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case. ( 27980740 )
2016
43
Apparent diffusion coefficient map of a case of extramedullary plasmacytoma. ( 27200157 )
2016
44
Feline Respiratory Extramedullary Plasmacytoma with Lymph Node Metastasis and Intrahistiocytic Amyloid. ( 28017340 )
2016
45
Primary Extramedullary Plasmacytoma in the Gastroduodenal Canal Associated With Epstein-Barr Virus-Associated Adenocarcinoma of the Stomach: A Case Report. ( 27466321 )
2016
46
Solitary extramedullary plasmacytoma of the colon, rectum and anus. ( 28240504 )
2016
47
Endoscopic ultrasound-fine needle aspiration: A novel way to diagnose a solitary extramedullary plasmacytoma of the liver. ( 27080614 )
2016
48
Extramedullary Plasmacytoma of the Paranasal Sinuses: Combining Surgery with External Radiotherapy. ( 27066407 )
2016
49
Primary Plurifocal Extramedullary Plasmacytoma of Breast. ( 27059937 )
2016
50
Establishment of an innovative staging system for extramedullary plasmacytoma. ( 27717354 )
2016

Variations for Extramedullary Plasmacytoma

Expression for Extramedullary Plasmacytoma

Search GEO for disease gene expression data for Extramedullary Plasmacytoma.

Pathways for Extramedullary Plasmacytoma

Pathways related to Extramedullary Plasmacytoma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.08 B2M BCL2 CCND1 CDKN1A IL6
2
Show member pathways
12.77 BCL2 CCND1 CDKN1A IL6
3
Show member pathways
12.69 B2M BCL2 CCND1 CDKN1A IL6
4 12.59 BCL2 CCND1 CDKN1A IL6
5
Show member pathways
12.52 BCL2 CCND1 CDKN1A IL6
6
Show member pathways
12.39 BCL2 CCND1 CDKN1A
7
Show member pathways
12.38 BCL2 CDKN1A IL6
8 12.31 BCL2 CCND1 CDKN1A
9 12.23 CCND1 CDKN1A IL6
10
Show member pathways
12.2 CCND1 CDKN1A IGKC
11
Show member pathways
12.18 BCL2 CCND1 CDKN1A
12
Show member pathways
12.1 BCL2 CCND1 CDKN1A IL6
13
Show member pathways
12.06 BCL2 CCND1 CDKN1A
14
Show member pathways
12.01 BCL2 CCND1 CDKN1A
15 11.99 CCND1 CDKN1A IL6
16 11.97 CCND1 CDKN1A IL6
17 11.95 BCL2 CCND1 CDKN1A
18
Show member pathways
11.92 CCND1 CDKN1A IL6
19
Show member pathways
11.87 BCL2 CDKN1A IL6
20
Show member pathways
11.87 CCND1 CDKN1A IL6
21 11.77 BCL2 CCND1 CDKN1A
22 11.73 BCL2 CDKN1A IL6
23 11.69 BCL2 CDKN1A IL6
24 11.67 BCL2 CCND1 IL6
25 11.66 B2M BCL2 CCND1 CDKN1A IL6
26 11.62 BCL2 CCND1 CDKN1A
27 11.52 BCL2 CCND1 CDKN1A
28 11.51 BCL2 CCND1 CDKN1A IL6
29
Show member pathways
11.48 CCND1 IL6
30 11.37 CCND1 CDKN1A
31 11.33 BCL2 CDKN1A
32 11.33 BCL2 CCND1 CDKN1A
33 11.31 CCND1 CDKN1A
34 11.24 BCL2 CCND1 IL6
35 11.2 CCND1 IL6
36 11.19 CCND1 IL6
37 11.15 CCND1 CDKN1A
38 11.14 CCND1 CDKN1A IL6
39
Show member pathways
10.97 BCL2 CDKN1A
40 10.89 BCL2 IL6
41 10.63 BCL2 CCND1 CDKN1A IL6

GO Terms for Extramedullary Plasmacytoma

Cellular components related to Extramedullary Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein kinase holoenzyme complex GO:0000307 8.62 CCND1 CDKN1A

Biological processes related to Extramedullary Plasmacytoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 humoral immune response GO:0006959 9.55 BCL2 IL6
2 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.54 BCL2 CDKN1A
3 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.52 CCND1 CDKN1A
4 animal organ regeneration GO:0031100 9.51 CCND1 CDKN1A
5 cellular response to organic substance GO:0071310 9.49 BCL2 CCND1
6 retina homeostasis GO:0001895 9.48 B2M IGKC
7 response to organonitrogen compound GO:0010243 9.46 CCND1 CDKN1A
8 response to drug GO:0042493 9.46 B2M BCL2 CCND1 CDKN1A
9 response to steroid hormone GO:0048545 9.43 BCL2 CCND1
10 T cell differentiation in thymus GO:0033077 9.4 B2M BCL2
11 response to X-ray GO:0010165 9.37 CCND1 CDKN1A
12 response to corticosterone GO:0051412 9.32 CCND1 CDKN1A
13 response to iron ion GO:0010039 9.26 BCL2 CCND1
14 cytokine-mediated signaling pathway GO:0019221 9.26 BCL2 CCND1 CDKN1A IL6
15 response to glucocorticoid GO:0051384 8.92 BCL2 CCND1 CDKN1A IL6

Molecular functions related to Extramedullary Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase activity GO:0004693 8.62 CCND1 CDKN1A

Sources for Extramedullary Plasmacytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....